The goal of this clinical trial is to learn if a plant-based intensive lifestyle intervention can achieve remission of diabetes. It will also learn if a plant-based intensive lifestyle intervention can achieve weight loss ≥15% of initial body weight. The main questions it aims to answer are: * What proportion of participants achieved diabetes remission (normal blood sugar for at least 3 months without medication)? * What proportion of participants achieved ≥15% weight loss from their initial weight? * What is the impact on weight, body composition, blood pressure, blood sugars, cholesterol and inflammation levels? Researchers will compare the plant-based intensive lifestyle intervention to the current standard of care. Participants will be randomly placed into one of two groups: 1. Standard of care, where they will continue their usual diabetes care with their health care providers 2. Plant-based intensive lifestyle intervention, where they will follow a diet and exercise program Participants in the standard of care will: * Continue with their usual diabetes care for 12 months * Attend clinic visits on 5 occasions over the 12 months * Allow study staff to take measurements (e.g. weight, blood pressure) * Provide blood samples * Track their food and exercise and complete questionnaires Participants in the plant-based intensive lifestyle intervention will: * Follow a plant-based low calorie diet for 3 months followed by a calorie-balanced plant-based diet for 9 months * Participate in a 16-week exercise program * Attend clinic visits every 2-4 weeks over the 12 months * Allow study staff to take measurements (e.g. weight, blood pressure) * Provide blood sample * Track their food and exercise and complete questionnaires
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
160
The plant-based intensive lifestyle intervention has 2 phases. The first 12-weeks is a weight loss phase consisting of a plant-based, high-plant protein energy restricted total diet replacement (TDR), psyllium-based fibre and complete multivitamin supplements, and vegetable bouillon, with the option of continuing with this phase up to week 20. The second phase is weight-loss maintenance beginning with an 8-week (weeks 12-20) stepped food reintroduction phase with partial meal replacement, progressing towards the 32-week (weeks 20-52) full food introduction phase. These phases focus on introducing a plant-based, high-plant protein, energy balanced, weight loss maintenance diet, which will be supported by a digital program. At weeks 12-28, a 16-week in-person structured exercise training program will be delivered followed by 2-weekly motivational phone calls until the 52-weeks. A 19-session, group-based, structured behavioural support program will be delivered throughout the study.
Participants will continue to receive usual diabetes and obesity management as per current Canadian clinical practice guidelines. The management will continue to be delivered to participants through their family doctor, nurse practitioner, or diabetes care team with standard frequency of contact. Participants will attend clinic visits on 5 occasions (weeks 0, 12, 28, 40 and 52) and will receive motivational phone calls between visits to provide reminders regarding follow-up with their diabetes care providers.
Unity Health Toronto (St. Michael's Hospital)
Toronto, Ontario, Canada
Proportion achieving diabetes remission
Proportion achieving diabetes remission, defined as an HbA1C \<6.5% for ≥3 months free of antihyperglycemic medications at 52 weeks.
Time frame: From enrollment to the end of treatment at 52 weeks.
Key secondary: Proportion achieving ≥15% weight loss
Proportion achieving ≥15% weight loss from baseline at 52 weeks.
Time frame: From enrollment to the end of treatment at 52 weeks.
Proportion achieving ≥10% and ≥5% weight loss from baseline change
Proportion achieving ≥10% and ≥5% weight loss from baseline at 52 weeks
Time frame: From enrollment to the end of treatment at 52 weeks
Changes in measures of body composition
Changes in body weight
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in body mass index
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in waist circumference
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in body fat
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in lean body mass
Time frame: From enrollment to the end of treatment at 52 weeks.
Proportion experiencing relapse
Proportion experiencing relapse, defined as having achieved remission at any time during the trial but having an HbA1c ≥6.5% at 52 weeks.
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in functional tests
Changes in sit-stand chair
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in functional tests
Changes in grip test
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in glycemic control
Changes in HbA1c
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in glycemic control
Changes in fasting plasma glucose
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in blood lipids
Changes in LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol, total cholesterol and triglycerides.
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in blood pressure
Changes in systolic and diastolic blood pressure.
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in inflammation
Changes in c-reactive protein (CRP)
Time frame: From enrollment to the end of treatment at 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.